Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral capsule
intravenous injection |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associated_with |
neurotoxicity
hyperlipidemia hepatotoxicity nephrotoxicity hirsutism lymphoma risk gum hyperplasia |
| gptkbp:atccode |
L04 AD01
|
| gptkbp:available_on |
generic medication
|
| gptkbp:brand |
gptkb:Neoral
gptkb:Sandimmune |
| gptkbp:casnumber |
59865-13-3
|
| gptkbp:chemical_formula |
C62 H111 N11 O12
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
active infections
hypersensitivity to cyclosporine |
| gptkbp:developed_by |
fungus Tolypocladium inflatum
|
| gptkbp:discovered_by |
1970s
|
| gptkbp:dosage_form |
gptkb:cream
oral solution |
| gptkbp:duration |
varies by condition
|
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
cyclosporine
|
| gptkbp:interacts_with |
gptkb:fruit
certain antibiotics certain antifungal medications |
| gptkbp:is_monitored_by |
blood pressure
kidney function drug levels |
| gptkbp:lifespan |
8 to 12 hours
|
| gptkbp:mechanism_of_action |
inhibits T-cell activation
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:produced_by |
gptkb:Novartis
|
| gptkbp:safety |
Category C
|
| gptkbp:side_effect |
high blood pressure
increased risk of infections kidney toxicity |
| gptkbp:suitable_for |
pregnancy
breastfeeding severe liver disease severe renal impairment malignancy history |
| gptkbp:used_for |
treating autoimmune diseases
preventing organ transplant rejection |
| gptkbp:used_in |
gptkb:Crohn's_disease
gptkb:ulcerative_colitis gptkb:rheumatoid_arthritis gptkb:multiple_sclerosis psoriasis dry eye syndrome heart transplants kidney transplants liver transplants |
| gptkbp:bfsParent |
gptkb:ketoconazole
|
| gptkbp:bfsLayer |
4
|